Balloon mis-positioning during prostate cancer treatment could affect success of radiation delivery

November 12, 2013 by Garth Sundem

A University of Colorado Cancer Center study recently published in the journal Physics in Medicine and Biology shows that endorectal balloons commonly used during precise radiation treatment for prostate cancer can deform the prostate in a way that could make radiation miss its mark.

"Use of a balloon allows you to stabilize the anatomy. But what we show is that imprecision with balloon placement could reduce radiation dose coverage over the intended area," says Moyed Miften, PhD, FAAPM, investigator at the CU Cancer Center and chief physicist at the University of Colorado School of Medicine Department of Radiation Oncology.

Specifically, Miften and colleagues including Bernard Jones, Gregory Gan, and Brian Kavanagh studied the technique known as stereotactic body radiation, in which powerful, precisely-targeted radiation is delivered only to cancerous areas of the with the hope of killing tumor tissue. An endorectal balloon is needed to hold the prostate in place while this high dose is delivered. The study used 71 images of 9 patients to show an average endorectal balloon placement error of 0.5 cm in the inferior direction. And these placement errors led to less precise radiation targeting and to uneven coverage over cancerous areas.

"In , we use a CT scan to image a patient's prostate and then plan necessary treatment. But if during treatment the prostate doesn't match this planning image, we can deliver an imprecise dose," Miften says.

With the use of endorectal balloon, Miften and colleagues found prostates could be slightly pushed or squeezed, resulting in the prostate deforming slightly from its original shape and also sometimes tilting slightly from its original position in the body. These deformations can push parts of the prostate outside the area reached by the planned radiation.

"What we see is that whether or not a clinician chooses to use an endorectal balloon along with stereotactic body radiation for , it's essential to perform the procedure with image guidance. The key is acquiring images immediately prior to treatment that ensure the anatomy matches the planning CT," Miften says.

Explore further: Biodegradable implant may lessen side effects of radiation to treat prostate cancer

More information: iopscience.iop.org/0031-9155/58/22/7995/

Related Stories

Biodegradable implant may lessen side effects of radiation to treat prostate cancer

June 10, 2013
Several years ago, Virginia Commonwealth University Massey Cancer Center became the first center in the United States to test an Israeli-invented device designed to increase the space between the prostate and the rectum in ...

Tissue spacers reduce risk of rectal injury for prostate cancer patients

April 29, 2011
Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer ...

A promising step forward in prostate cancer treatment

August 6, 2012
When treating prostate cancer with radiotherapy, knowing the prostate cancer position is critical to accurately targeting the radiation beam to avoid missing the tumour and irradiating healthy tissue. Prostate cancer patients ...

Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence

June 26, 2012
A recent Phase I/II clinical trial has shown that a new combination of radiation therapies developed at Virginia Commonwealth University Massey Cancer Center escalates radiation doses to safely and effectively treat prostate ...

Weight at time of diagnosis linked to prostate cancer mortality

October 29, 2013
Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal ...

Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy

May 20, 2013
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.